| dc.contributor.author | Tyndall, M | |
| dc.contributor.author | Malisa, M | |
| dc.contributor.author | Plummer, FA | |
| dc.contributor.author | Ombetti, J | |
| dc.contributor.author | Ndinya-Achola, JO | |
| dc.contributor.author | Ronald, AR | |
| dc.date.accessioned | 2013-04-26T09:15:09Z | |
| dc.date.available | 2013-04-26T09:15:09Z | |
| dc.date.issued | 1993 | |
| dc.identifier.citation | J Infect Dis. 1993 Feb;167(2):469-71 | en |
| dc.identifier.uri | http://hinari-gw.who.int/whalecomwww.ncbi.nlm.nih.gov/whalecom0/pubmed/8421184 | |
| dc.identifier.uri | http://erepository.uonbi.ac.ke:8080/xmlui/handle/123456789/16985 | |
| dc.description.abstract | Ceftriaxone in a dose of 250 mg given intramuscularly is currently recommended for the treatment of chancroid. Among 133 men in Nairobi, Kenya, with culture-proven chancroid, who were treated with ceftriaxone, treatment failed in 35%. Poor outcome was associated with human immunodeficiency virus type 1 seropositivity. Thus, treatment recommendations for chancroid should be reevaluated. | en |
| dc.language.iso | en | en |
| dc.title | Ceftriaxone no longer predictably cures chancroid in Kenya. | en |
| dc.type | Article | en |
| local.publisher | Department of Medicine, University of Manitoba, Winnipeg, Canada. | en |
